Alert detail
LCD L39389: MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma — CGS
What changed
New LCD impacts melanoma molecular assay billing.
Who’s affected: Oncology billing teams · Effective: April 16, 2026
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 5 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.